Form 4: Allogene CTO Sells Shares for Tax Obligations

Allogene Therapeutics' SVP and Chief Technical Officer, Benjamin Beneski, sold 4,835 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Benjamin Machinas Beneski, SVP, Chief Technical Officer of Allogene Therapeutics, Inc. (ALLO), reported a transaction.
• On March 16, 2026, Beneski sold 4,835 shares of Allogene Therapeutics common stock.
• The shares were sold at a weighted average price of $2.47 per share, with individual transactions ranging from $2.46 to $2.47.
• This sale was mandated by the Issuer's equity incentive plan to satisfy tax withholding obligations in connection with the vesting of restricted stock units and was not a discretionary trade.
• Following this transaction, Beneski beneficially owns 198,205 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes, which does not reflect a change in the reporting person's investment sentiment or the company's operational performance. Therefore, the sentiment is neutral.

Positives

• The vesting of restricted stock units indicates that the company's equity compensation plan is functioning as intended, which can be a positive for employee retention and motivation.

Negatives

• The sale of shares, even for tax purposes, results in a slight reduction of the officer's direct beneficial ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and routine occurrence for executives receiving equity compensation, such as restricted stock units. These sales are typically non-discretionary and are executed solely to satisfy tax withholding obligations upon the vesting of equity awards, rather than reflecting a change in management's investment sentiment or outlook on the company's future prospects.

Comparison to Industry Standards

• This 'sell to cover' transaction aligns with standard practices for executive compensation and tax management across various industries, including biotechnology. Companies like Gilead Sciences, Amgen, and Biogen frequently see similar non-discretionary sales by their executives when equity awards vest, as it's a common mechanism to fund tax liabilities without requiring the executive to use personal funds.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal as this is a small, non-discretionary sale for tax purposes and does not indicate a change in the company's operational or strategic direction.
• Employees: The transaction indicates that the company's equity incentive plan is functioning, which is a standard component of executive compensation.

Key Dates

Recommendation

This Form 4 reports a routine "sell to cover" transaction by an executive to satisfy tax obligations upon the vesting of restricted stock units. It is not a discretionary sale and therefore does not provide new information that would alter the fundamental investment outlook for Allogene Therapeutics, Inc. Investors should maintain their current position based on broader company fundamentals and market conditions.

Keywords

Allogene Therapeutics, ALLO, Form 4, insider transaction, stock sale, restricted stock units, RSU, tax withholding, Benjamin Beneski